Abstract: An assembly having a tube and at least one optical cable with the optical cable being placed inside the tube. The tube has an inner diameter D and in that the optical cable has an outer diameter d, the ratio d/D ranging from 0.10 to 0.80.

Abstract: An assembly having a tube and at least one optical cable with the optical cable being placed inside the tube. The tube has an inner diameter D and in that the optical cable has an outer diameter d, the ratio d/D ranging from 0.10 to 0.80.

Abstract: An assembly has a tube and at least one optical cable, the optical cable being placed inside the tube. The tube has a main layer comprising one first polymer material, the first polymer material having at least one polymer of polyimide.

Abstract: An electric cable is providing having at least one elongated electrically conducting element containing a plurality of electrically conducting strands and at least one fluorinated polymer layer surrounding said elongated electrically conducting element, said cable further comprising a metallic layer comprising nickel interposed between the elongated electrically conducting element and the fluorinated polymer layer, and a method of manufacturing said cable.

Abstract: The subject of the invention is a data communications cable, characterized in that it comprises: a plurality of groups (1,2,3,4) of four pairs of isolated conductors, the four pairs of isolated conductors being assembled in a helical fashion following a group assembly pitch, each pair being twisted in a helical fashion and surrounded by an electrical shield (9,10), the plurality of groups (1,2,3,4) being assembled in a helical fashion following a final assembly pitch, an external sheath (8) surrounding the plurality of groups (1,2,3,4), the final assembly pitch being variable along the cable.

Abstract: The invention relates to a compound of formula A-R—X or pharmaceutically acceptable salts thereof which can be used for producing a pharmaceutical preparation suitable for preventing or treating cancerous diseases, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases, hepatic insulin resistance in diabetes mellitus, hepatic damage in Wilson's disease and sideroses and/or ischaemic reperfusion damage, as an antidote against environmental toxins and medicament intoxication in order to extend the resistance time of medicaments in organisms, or for combating toxic side effects in the administration of chemotherapeutics. In the formula R is an aliphatic or aromatic C6- to C40-hydrocarbon radical which has a hydrophilic end A, and X is a radical having at least one free electron pair of a carbon or heteroatom and/or ?-electrons.

Abstract: A helically-wound electric cable having at least two groups wound together so as to form a group helix. Each group has at least two twisted-together conductor wires, wherein the pitch of the group helix varying along the helically-wound electric cable in accordance with a sinusoidal function between two limit values having the same sign, characterized in that said sinusoidal function has a determined modulation period (MP) in order to avoid return loss peak (RLp) in the operating frequency range (Fmin-Fmax) of said helically-wound electric cable.

Abstract: The present invention concerns a helically-wound electric cable comprising at least two groups wound together so as to form a group helix, each group comprising at least two twisted-together conductor wires, the pitch of the group helix varying along the helically-wound electric cable in accordance with a sinusoidal function between two limit values having the same sign, characterized in that said sinusoidal function has a determined modulation period (MP) in order to avoid return loss peak (RLp) in the operating frequency range (Fmin-Fmax) of said helically-wound electric cable.

Abstract: A compound of the formula (1) or pharmaceutically acceptable salts thereof can be used for producing a pharmaceutical preparation for preventing or treating cancerous diseases, pathological sequelae of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal disorders, hepatic insulin resistance in diabetes mellitus, liver damage associated with Wilson's disease and/or sideroses, ischemic reperfusion damage, for use as an antidote to environmental toxins and prescription drug intoxication, for prolonging the retention time of drugs in the organism, and/or for combating toxic side effects on administration of chemotherapeutic agents. B6, B7 and B8 are identical or different and denote O, S, NH, PO4, Se, SO4. R1 is identical to H or a C6 and/or C7 to C26 and/or C20 alkyl chain; and R2, R3, R4 and R5 can be identical or different and denote an H or a C1 to C3 alkyl, alkanol, alkylamine and/or alkyl thiol group.

Abstract: The invention relates to a compound of formula A-R-X or pharmaceutically acceptable salts thereof which can be used for producing a pharmaceutical preparation suitable for preventing or treating cancerous diseases, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases, hepatic insulin resistance in diabetes mellitus, hepatic damage in Wilson's disease and sideroses and/or ischaemic reperfusion damage, as an antidote against environmental toxins and medicament intoxication in order to extend the resistance time of medicaments in organisms, or for combating toxic side effects in the administration of chemotherapeutics. In the formula R is an aliphatic or aromatic C6- to C40-hydrocarbon radical which has a hydrophilic end A, and X is a radical having at least one free electron pair of a carbon or heteroatom and/or ?-electrons.

Abstract: A pharmaceutical preparation is disclosed for the prevention, treatment and relief from the consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, Alzheimer's disease, Parkinson's disease, toxic kidney diseases, acute kidney failure, toxic side effects on dosage of chemotherapeutics, diabetes mellitus, Wilson's disease, sideroses and/or ischaemic reperfusion damage, arteriosclerosis and as an antidote against environmental toxins and medicament intoxication. The preparation comprises at least one compound of general formula R-A-X, as active ingredient, where R=straight or branched chain C5-C27 alkyl with double and/or triple bonds and which can be substituted, A=—CO—, —COO—, —POx2?—, —NHy—, —O— and/or —S—, x=2, 3 or 4, y=1 or 2 and X?H, polyol, amino acid, alkylamino, C1- to C3-alkylamino, C1- to C3 hydroxyalkyl and/or 1- to C3-carboxylic acid.